---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-125170"
form_type: "8-K"
ticker: "LQDA"
cik: "0001819576"
company_name: "Liquidia Corp"
filed_at: "2023-12-12T23:59:59+00:00"
generated_at: "2026-06-07T14:20:15.543673+00:00"
event_type: "litigation"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Liquidia faces new PH-ILD patent infringement suit from United Therapeutics on '327 Patent

## Summary
- United Therapeutics filed amended complaint Nov 30, 2023, alleging YUTREPIA infringes new '327 Patent covering inhaled treprostinil for PH-ILD.
- The '327 Patent issued Nov 28, 2023; Liquidia argues no 30-month stay because it issued after original NDA filing.
- Ongoing IPR of '793 Patent: PTAB ruled claims unpatentable; appeal pending at Federal Circuit after Dec 4, 2023 oral argument.
- Liquidia intends to vigorously defend; previous Hatch-Waxman ruling still blocks YUTREPIA approval for PH-ILD.

## SEC filing metadata
- accession: 0001104659-23-125170
- form_type: 8-K
- ticker: LQDA
- cik: 0001819576
- company_name: Liquidia Corp
- filed_at: 2023-12-12T23:59:59+00:00
- event_type: litigation
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819576/000110465923125170/0001104659-23-125170-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819576/000110465923125170/tm2332679d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-125170
- JSON: https://secwatch.observer/filing/0001104659-23-125170.json
- Plain text: https://secwatch.observer/filing/0001104659-23-125170.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.